Literature DB >> 26877232

Extensive tumoral melanosis associated with ipilimumab-treated melanoma.

K Staser1, D Chen1, J Solus1,2, I S Rosman1,2, A Schaffer1,2, L Cornelius1, G P Linette3, R C Fields4.   

Abstract

Tumoral melanosis describes a pigmented lesion clinically similar to melanoma but on histology reveals dense aggregates of melanin-laden, benign macrophages without malignant cells. In the few reported cases so far, tumoral melanosis has arisen in the skin or lymph node of a patient with a regressed melanoma or an epithelioid tumour. As a marker of regressed primary melanoma, its discovery may prompt investigation and surveillance for undiagnosed local or metastatic disease. Here, we present a unique case of extensive tumoral melanosis arising during ipilimumab treatment of in-transit metastases from a previously excised melanoma.
© 2016 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26877232     DOI: 10.1111/bjd.14474

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.

Authors:  Hajir Ibraheim; Esperanza Perucha; Nick Powell
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 2.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527

3.  Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma.

Authors:  Omar Bari; Philip R Cohen
Journal:  Cureus       Date:  2017-02-13

4.  Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma.

Authors:  Antonia Laino; Benjamin Shepherd; Victoria Atkinson; Hong Fu; H Peter Soyer; Helmut Schaider
Journal:  JAAD Case Rep       Date:  2018-10-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.